These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251 [TBL] [Abstract][Full Text] [Related]
6. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582 [TBL] [Abstract][Full Text] [Related]
7. Localization of Unknown Primary Site with Menda Y; O'Dorisio TM; Howe JR; Schultz M; Dillon JS; Dick D; Watkins GL; Ginader T; Bushnell DL; Sunderland JJ; Zamba GKD; Graham M; O'Dorisio MS J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957 [TBL] [Abstract][Full Text] [Related]
8. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627 [TBL] [Abstract][Full Text] [Related]
9. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan. Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Schreiter NF; Nogami M; Steffen I; Pape UF; Hamm B; Brenner W; Röttgen R Eur Radiol; 2012 Feb; 22(2):458-67. PubMed ID: 21904802 [TBL] [Abstract][Full Text] [Related]
11. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor. Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778 [TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704 [TBL] [Abstract][Full Text] [Related]
13. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Froeling V; Elgeti F; Maurer MH; Scheurig-Muenkler C; Beck A; Kroencke TJ; Pape UF; Hamm B; Brenner W; Schreiter NF Ann Nucl Med; 2012 Nov; 26(9):738-43. PubMed ID: 22865406 [TBL] [Abstract][Full Text] [Related]
14. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768 [TBL] [Abstract][Full Text] [Related]
15. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343 [TBL] [Abstract][Full Text] [Related]
16. Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by Jahn U; Ilan E; Velikyan I; Fröss-Baron K; Lubberink M; Sundin A EJNMMI Res; 2021 Nov; 11(1):118. PubMed ID: 34822040 [TBL] [Abstract][Full Text] [Related]
17. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors. Müssig K; Oksüz MO; Dudziak K; Ueberberg B; Wehrmann M; Horger M; Schulz S; Häring HU; Pfannenberg C; Bares R; Gallwitz B; Petersenn S Horm Metab Res; 2010 Jul; 42(8):599-606. PubMed ID: 20422506 [TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability and clinical implementation of 'ready-to-use' Manoharan P; Lamarca A; Navalkissoor S; Calero J; Chan PS; Julyan P; Sierra M; Caplin M; Valle J ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32188715 [TBL] [Abstract][Full Text] [Related]
19. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1. Albers MB; Librizzi D; Lopez CL; Manoharan J; Apitzsch JC; Slater EP; Bollmann C; Kann PH; Bartsch DK World J Surg; 2017 Jun; 41(6):1521-1527. PubMed ID: 28138732 [TBL] [Abstract][Full Text] [Related]
20. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]